MIT and Recursion have released Boltz-2, the first biomolecular co-folding model that simultaneously predicts molecular structure and binding affinity with remarkable accuracy, approaching that of ...

The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites ...